RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers

a study on Aneurysm

Summary

for people ages 18 years and up (full criteria)
at Irvine, California and other locations
study started
estimated completion

Description

Summary

Investigate the safety and effectiveness of the RelayPro Thoracic Stent-Grafts in subjects with thoracic aortic aneurysms (TAA) and penetrating atherosclerotic ulcers (PAU) of the descending thoracic aorta.

Official Title

A Prospective, Multicenter, Non-Blinded, Non-Randomized Study of the RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers

Details

The objective of this study is to investigate the safety and effectiveness of the RelayPro Thoracic Stent-Grafts in subjects with thoracic aortic aneurysms and penetrating atherosclerotic ulcers of the descending thoracic aorta.

Keywords

Aortic Aneurysm, ThoracicAneurysmAortic AneurysmRelayPro

Eligibility

You can join if…

Open to people ages 18 years and up

  • Subject must be ≥ 18 years of age
  • Subject has specified disease in his/her descending thoracic aorta.
  • Subject have anatomical compliance for the device specified for both access vessels and treatment area.
  • Subject must be willing to comply with the follow-up evaluation schedule.
  • Subject (or Legally Authorized Representative) agrees an Informed Consent Form prior to treatment.

You CAN'T join if...

  • Subject has specified disease of the thoracic aorta which is not included in the trial, for example: aortic dissection, intramural hematoma, traumatic injury or transection, aortic false aneurysm, ruptured aneurysm.
  • Subject anatomy with significant stenosis, calcification, thrombus or tortuosity.
  • Subjects with specified compromised circulation.
  • Subjects with specified prior procedures.
  • Subjects with allergy to contrast media or device components.
  • Subjects with disease, for example: suspected connective tissue disorder, specified coagulation disorders, specified coronary artery disease, severe congestive heart failure, stroke and/or Myocardial Infarction (MI) as specified, specified pulmonary disease, specified renal failure.
  • Subjects that are pregnant or planning to become pregnant during the course of the study.

Locations

  • University of California, Irvineaccepting new patients
    IrvineCalifornia92868United States
  • Long Beach Memorial Hospitalnot yet accepting patients
    Long BeachCalifornia90806United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bolton Medical
ID
NCT02818972
Study Type
Interventional
Last Updated